Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis. Science ShareTwitterFacebookXingLinkedin You May Also Like Science 25. Mai 2023 CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes Science 25. Mai 2023 Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies. Science 25. Mai 2023 (Bersacapavir) In Participants With Moderate Hepatic Impairment.
